ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0412

Impact of Approval of Biologic DMARDs on JIA Outcomes in a Single Center

Anna Sutton1, Erin Balay-Dustrude1, Beth A Mueller1 and Susan Shenoi2, 1University of Washington, Seattle, WA, 2Seattle Children's Hospital and Research Center, Mercer Island, WA, WA

Meeting: ACR Convergence 2024

Keywords: Biologicals, Disease Activity, Epidemiology, Juvenile idiopathic arthritis, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Pediatric Rheumatology – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: In clinical trials, biologic disease-modifying antirheumatic drugs (bDMARDs) for juvenile idiopathic arthritis (JIA) have demonstrated good efficacy. However, less is known about the impact of the increasing use of bDMARDs on JIA outcomes outside of clinical trial settings. We examined selected outcomes among children with JIA after bDMARD availability compared to those prior to bDMARD availability.

Methods: This retrospective cohort study assessed two JIA cohorts representing pre- and post-bDMARD availability for achievement of, elapsed time until, and time in inactive disease, along with disease flare after achieving inactive disease status. The pre-bDMARD cohort included children diagnosed with JIA 1998-2000 (N=116); the post-bDMARD cohort included children diagnosed 2015-2017 (N=182). Diagnosis dates and outcomes were abstracted for children with 2 years of follow up post-diagnosis. Mean days to inactive disease and time in inactive disease were compared using t-tests. Poisson regression estimated relative risks (RRs) and 95% confidence intervals (CIs) for outcomes post- compared to pre-bDMARD availability, adjusting for diagnosis age, JIA category (polycourse vs persistent oligoarthritis), and receipt of intraarticular glucocorticoid injection.

Results: Children in the post-bDMARD cohort were more likely to be older, male, with polycourse arthritis, and more likely prescribed conventional DMARDs and glucocorticoids but less likely to have intraarticular glucocorticoid injections. 57% of children in the post-bDMARD cohort were prescribed a bDMARD during follow up. Mean elapsed time to inactive disease in the post-bDMARD cohort was 277 days (SD+244) vs 311 days (SD+299) in the pre-bDMARD cohort (p=0.2). Mean time in inactive disease during follow-up in the bDMARD cohort was 371 days (SD 226) vs 360 days (SD 213) in the pre-bDMARD cohort (p=0.7). Adjusted RRs of achieving inactive disease or occurrence of post-remission flare in the bDMARD cohort were 0.98 (95%CI: 0.92, 1.05) and 1.15 (95%CI 0.94-1.43), respectively. Results did not vary by age (0-5 yrs, 5-10 yrs, 11-16 yrs), sex or race/ethnicity, although flare risks for polycourse (RR 1.07, 95%CI 0.82-1.39) and persistent oligoarticular (RR 1.34, 95%CI 0.95-1.89) differed slightly.

Conclusion: Although mean days to inactive disease decreased, and mean days with inactive disease slightly increased for children in the bDMARD era, achievement of inactive disease did not significantly differ between the groups. Unexpectedly, the proportion of children with disease flares after remission was slightly, but not significantly larger in the post-bDMARD cohort, particularly for those with persistent oligoarticular JIA. Although limited by small numbers and proxy bDMARD exposure assessment, our results demonstrate a reduction in the number of days of disease-related suffering among children with JIA receiving care post-bDMARD availability, and suggest further development of targeted regimens for children with persistent oligoarticular JIA are needed.

Supporting image 1

Table 1

Supporting image 2

Table 2


Disclosures: A. Sutton: None; E. Balay-Dustrude: None; B. Mueller: AstraZeneca, 12, Spouse holds few shares of stock in company.; S. Shenoi: cabletta, 2, Cure JM Foundation, 12, COE support at SCH, Pfizer, 2.

To cite this abstract in AMA style:

Sutton A, Balay-Dustrude E, Mueller B, Shenoi S. Impact of Approval of Biologic DMARDs on JIA Outcomes in a Single Center [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/impact-of-approval-of-biologic-dmards-on-jia-outcomes-in-a-single-center/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-approval-of-biologic-dmards-on-jia-outcomes-in-a-single-center/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology